Adverum Biotechnologies, Inc.
ADVM
$2.91
-$0.06-2.02%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -100.00% | -- | |||
| Cost of Revenue | 17.89% | 19.55% | |||
| Gross Profit | -23.95% | -13.70% | |||
| SG&A Expenses | 289.72% | 158.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 105.87% | 44.72% | |||
| Operating Income | -112.92% | -39.93% | |||
| Income Before Tax | -123.08% | -46.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -123.08% | -46.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -123.08% | -46.86% | |||
| EBIT | -112.92% | -39.93% | |||
| EBITDA | -116.75% | -42.18% | |||
| EPS Basic | -122.83% | -46.69% | |||
| Normalized Basic EPS | -122.83% | -46.70% | |||
| EPS Diluted | -122.83% | -46.69% | |||
| Normalized Diluted EPS | -122.83% | -46.70% | |||
| Average Basic Shares Outstanding | 0.11% | 0.12% | |||
| Average Diluted Shares Outstanding | 0.11% | 0.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||